Source: Mesoblast/LinkedIn
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • The US FDA rejects Mesoblast’s (MSB) resubmission of its Biologics License Application (BLA) for its novel drug candidate, remestemcel-L
  • The body reported it requires more data to support marketing approval to use the drug for pediatric steroid-refractory acute graft versus host disease (SR-aGVHD)
  • Mesoblast will conduct a targeted and controlled study using the highest-risk adult participants where existing treatment has not improved outcomes
  • The company will seek feedback from the FDA on its trial design for its adult study within 45 days
  • MSB shares are down 54.6 per cent, trading at 49.5 cents at 2:44 pm AEST

The US Food and Drug Administration (FDA) has rejected Mesoblast’s (MSB) resubmission of its Biologics License Application (BLA) for novel drug candidate, remestemcel-L.

The body stated it required more data to support marketing approval to use the drug for pediatric steroid-refractory acute graft versus host disease (SR-aGVHD).

In order to do so, Mesoblast reported it will conduct a targeted, controlled study using the highest-risk adult participants where existing treatment has not improved outcomes.

Adults comprise 80 per cent of the SR-aGVHD market and MSB is a global leader in allogeneic cellular medicines for inflammatory diseases.

The adult study falls in line with Mesoblast’s overall commercial strategy, which envisions a sequenced progression from pediatric to adult SR-aGVHD indications.

“The FDA’s inspection of our manufacturing process resulted in no observed concerns, the agency raised no safety issues across more than 1300 patients who have received remestemcel-L to date and it acknowledged improvements to our potency assay,” MSB Chief Executive Silviu Itescu said.

“We remain steadfast in making remestemcel-L available to both children and adults suffering from this devastating disease, and have received substantial clarity in how to bring this much-needed product to these patients”.

Prior to the resubmission, the FDA guided Mesoblast to resolve outstanding chemistry, manufacturing and control (CMC) issues before initiating any additional clinical trial.

Despite knocking back the resubmission, the FDA did acknowledge in its review the company had made some improvements to assay performance compared to previous versions used in its pediatric phase three trial.

The new adult study will use previously generated pilot data through Mesoblast’s emergency IND program in adults, which displayed strong survival benefits using remestemcel-L.

Mesoblast has revealed it’s already working with leading investigators at various US centres to establish adult follow-on study protocol, and will potentially utilise established clinical trial networks.

The company announced it would seek alignment with FDA on the trial design for its adult study in an upcoming meeting with the body within 45 days.

MSB shares were down 54.6 per cent, trading at 49.5 cents at 2:44 pm AEST.

msb by the numbers
More From The Market Online

Resolution drilling strengthens growing Golden Gate North gold system

Resolution Minerals strengthens gold continuity at Golden Gate North with broad drill intersections, while 30 assays…

Bounty Oil & Gas identifies multiple exploration leads with Sunfish 3D seismic data

Bounty Oil & Gas has identified multiple leads to follow-up in its technical due diligence program…
The Market Online Video

Market Close: ASX slides as technology and materials stocks lead broad market decline

The Australian share market finished lower on Wednesday, with the S&P/ASX 200 falling 0.69% to close at 8,821.80 points.

Zeus Resources mobilise rig for maiden drilling at Diaguili project in Mauritania

Zeus Resources is on target to kick-off a maiden diamond drill program with the rig mobilised…